Targretin Gel

Targretin Gel is a brand name of bexarotene topical, approved by the FDA in the following formulation(s):

TARGRETIN (bexarotene - gel; topical)

• 
  Manufacturer: EISAI INC
  
  Approval date: June 28, 2000
  
  Strength(s): 1% ^[RLD]

Has a generic version of Targretin Gel been approved?

No. There is currently no therapeutically equivalent version of Targretin Gel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Targretin Gel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
  Patent 5,780,676
  Issued: July 14, 1998
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A. & Zhi; Lin & Hwang; Chan Kou & White; Steve & Nadzan; Alex
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and poiyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • July 14, 2015
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 5,962,731
  Issued: October 5, 1999
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • October 5, 2016
    
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 6,043,279
  Issued: March 28, 2000
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Ligand Pharmaceuticals, Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 6,320,074
  Issued: November 20, 2001
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A. & Zhi; Lin & Koch; Stacie Canan
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
    ✓ 
    Drug substance
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 7,655,699
  Issued: February 2, 2010
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Eisai Inc.
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Targretin Gel Consumer Information (Wolters Kluwer)
• Targretin Topical Consumer Information (Cerner Multum)
• Targretin Topical Advanced Consumer Information (Micromedex)
• Targretin topical AHFS DI Monographs (ASHP)
• Bexarotene Gel Consumer Information (Wolters Kluwer)
• Bexarotene topical Consumer Information (Cerner Multum)
• Bexarotene Topical Advanced Consumer Information (Micromedex)
• Bexarotene topical AHFS DI Monographs (ASHP)